MIAMI, Jan. 20, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Firm”), a frontrunner in digital therapeutics, introduced in the present day the Firm has closed the transaction to promote 100% of its Mycotopia Remedy subsidiary to twenty/20 World Inc. (OTC Pink: TWGL). On account of the transaction closing, Ehave controls roughly 75.77% of the excellent shares of 20/20 World. 20/20 World Inc. plans to file with FINRA to vary the identify of the corporate to Mycotopia Remedy. Ehave, Inc. and 20/20 World will file relevant 8k and 6k filings for the transaction with the SEC and SEDAR.
Ehave Chairman and CEO Ben Kaplan will function Chairman and CEO of each Ehave and 20/20 World. All funds have been made and inventory certificates transferred to finish the transaction. Sooner or later, Ehave administration intends to current a plan to the Board to offer its shareholders a possibility to take part within the transaction. Particulars of the distribution of shares can be offered at a later date when particulars can be found. The Board of Administrators of 20/20 World has stepped down and Ben Kaplan has been named CEO of World 20/20, in addition to Ehave, Inc. Along with Mr. Kaplan, Mark Croskery has been appointed to the Board of Administrators of 20/20 World. Along with his obligations to the Board of 20/20 World, Mr. Croskery serves as Chairman and CEO of Croskery Capital Restricted in Kingston, Jamaica.
The transaction has been nicely acquired in Jamaica and was the topic of an article within the Jamaica Gleaner, a number one Jamaican newspaper that has been revealed since 1834. The article titled “Ehave Magic Mushroom Firm To Enter Jamaica – Faucets Croskery As Director Of Subsidiary, Kaya As Wellness Adviser And Accomplice” will be discovered at http://jamaica-gleaner.com/article/enterprise/20210115/ehave-magic-mushroom-company-enter-jamaica-taps-croskery-director.
20/20 World and Mycotopia Therapies can be a pure play on the psychedelic area and personal 10% of PsyTech, which produces of the psychedelic skilled conferences concerning the science of psychedelics and associated enterprise alternatives firm together with psychedelic tour and journey associated companies. Ehave will proceed develop Ketadash, the Ehave Dashboard, its MegaTeam online game purposes for kids with ADHD, the security and safety of Digital Well being Data (EHRs), bettering psychological well being, and combatting psychological sickness.
Ehave CEO Ben Kaplan mentioned “We stay up for creating Mycotopia’s marketing strategy as a stand-alone public firm. Our purpose is to develop the presence of each Ehave and 20/20 World as separate ecosystems within the psychedelic sector and proceed to develop new alternatives.” Mr. Kaplan continued, “We additionally plan to distribute a few of the 20/20 World shares held by Ehave to its shareholders. We’re contemplating a number of choices and can present extra info as soon as we have now ascertained essentially the most useful technique of distribution for our shareholders.”
Further Ehave Inc. Data
We’re actually grateful for the help of EHVVF shareholders! Please be a part of the dialog on our Ehave supporter’s telegram group at https://t.me/EhaveInc.
The corporate posts vital info and updates by weekly movies from the official firm YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.
Please observe Ehave on Twitter @Ehaveinc1
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a frontrunner of digital therapeutics delivering evidence-based therapeutic interventions to sufferers. Our major focus is on bettering the usual care in therapeutics to forestall or deal with mind issues or ailments by using digital therapeutics, independently or collectively, with medicines, gadgets, and different therapies to optimize affected person care and well being outcomes. Our important product is the Ehave Telemetry Portal, which is a psychological well being informatics platform that permits clinicians to make goal and clever choices by information insights. The Ehave Infinity Portal provides a robust machine studying and synthetic intelligence platform with a rising set of superior instruments and purposes developed by Ehave and its main companions. This empowers sufferers, healthcare suppliers, and payers to handle a variety of circumstances by prime quality, protected, and efficient data-driven involvement with clever and accessible instruments. Further info on Ehave will be discovered on the Firm’s web site at: www.ehave.com.
About Mycotopia Remedy
Mycotopia Remedy focuses on serving to you heal and reclaim your life. Your journey of therapeutic is an understanding of the causes and works to psychological wellness by psychedelic enhanced psychotherapy, built-in with knowledgeable crew of psychological wellness practitioners and cutting-edge know-how. Psychedelic remedy is a holistic and religious strategy offering therapeutic and has proven profitable remedy for a few years. Further info on Mycotopia Remedy will be discovered on the Firm’s web site at: https://www.mycotopiatherapies.com.
Ahead-Trying Assertion Disclaimer
This press launch comprises “forward-looking statements” inside the which means of the Non-public Securities Litigation Reform Act of 1995. Such statements could also be preceded by the phrases “intends,” “might,” “will,” “plans,” “expects,” “anticipates,” “tasks,” “predicts,” “estimates,” “goals,” “believes,” “hopes,” “potential” or related phrases. Ahead-looking statements are based mostly on sure assumptions and are topic to varied identified and unknown dangers and uncertainties, lots of that are past the Firm’s management, and can’t be predicted or quantified and consequently, precise outcomes might differ materially from these expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and outcomes of the Firm’s analysis, manufacturing and different growth efforts; (ii) the Firm’s means to advance its merchandise to efficiently full growth and commercialization; (iii) the manufacturing, growth, commercialization, and market acceptance of the Firm’s merchandise; (iv) the dearth of enough funding to finance the product growth and enterprise operations; (v) aggressive firms and applied sciences inside the Firm’s trade and introduction of competing merchandise; (vi) the Firm’s means to determine and preserve company collaborations; (vii) lack of key administration personnel; (viii) the scope of safety the Firm is ready to set up and preserve for mental property rights protecting its merchandise and its means to function its enterprise with out infringing the mental property rights of others; (ix) potential failure to adjust to relevant well being info privateness and safety legal guidelines and different state and federal privateness and safety legal guidelines; and (x) the issue of predicting actions of the USA FDA and its rules. All forward-looking statements included on this press launch are made solely as of the date of this press launch. The Firm assumes no obligation to replace any written or oral forward-looking assertion until required by legislation. Extra detailed details about the Firm and the danger components which will have an effect on the conclusion of forward-looking statements is contained below the heading “Danger Components” in Ehave, Inc.’s Registration Assertion on Type F-1 filed with the Securities and Change Fee (SEC) on September 24, 2015, as amended, which is on the market on the SEC’s web site, http://www.sec.gov.
Contact for Ehave Inc and 20/20 World
Media Inquiries: Gabe Rodriguez
Electronic mail: Ir@Ehave.com
Telephone: (623) 261-9046